Study Finds One Year of Heraceptin Breast Cancer Treatment is Best
A study has found that those with HER2-positive early breast cancer should stay on the drug Herceptin for one year, according to Medical News Today. The researchers conducted a Phase III HERA trial and found treatment for breast cancer with the Herceptin cancer treatment should last for one year instead of six months or two years.
Herceptin is used to treat patients with HER2-positive breast cancer. According to the article, about 25 percent of patients with HER2-postive breast cancer tumors are treated with this drug.
The trial showed that a two-year treatment with Herceptin had no advantage over treatment for only one year. Use of the medication had improved disease-free survival times as well as overall survival after treatment compared to women who were under observation alone, and there were no safety issues noted in the trial.
Disability from breast cancer can occur when the disease becomes serious and spreads to other body systems. Many who seek cancer treatment also develop disabling conditions related to the treatment such as chronic fatigue, pain, and complications from surgical removal of tumors or cancerous cells.
Those who develop a disabling condition related to breast cancer may qualify for Social Security disability benefits if their condition is severe enough to impair them from performing substantial gainful activity. If you or a loved one is suffering from a cancer-related health condition, you may wish to seek a Social Security disability representative to help evaluate your claim.
When you’re ready to get started with your Social Security disability claim, contact the Disability Help Group Our state-of-the-art, customized intake and database system means less hassle, so you can focus on what’s most important to you instead of having to spend your days wading through confusing legalese and legal red tape. Call today – 1-(800)-800-3332.